Craft

Eisai

Stock Price

$10.3

2024-03-28

Market Capitalization

$11.8 B

2024-03-28

Revenue

¥744.4 B

FY, 2023

Eisai Summary

Company Summary

Overview
Eisai is a research-based human health care company that discovers, develops, packages, and markets pharmaceutical products with a focus on neurology, oncology, Alzheimer's disease, epilepsy, and metabolic disorders. It offers a portfolio of tablets and injections for the treatment of various diseases. The company‘s areas of research and development focus include neuroscience, oncology, vascular, inflammatory and immunological reaction, and antibody-based programs.
Type
Public
Status
Active
Founded
1941
HQ
Bunkyo City, JP | view all locations
Website
https://www.eisai.com/
Cybersecurity rating
ESG rating
60-79 out of 100|View all ESG data
Sectors

Key People

  • Haruo Naito

    Haruo Naito, Director, Representative Corporate Officer and CEO

    • Tatsuyuki Yasuno

      Tatsuyuki Yasuno, Senior Vice President, President, Americas Region, President, Eisai Inc.

    • Kenta Takahashi

      Kenta Takahashi, Executive Vice President, General Counsel, Intellectual Property, Internal Audit

      • Bruce Aronson

        Bruce Aronson, Member of the Nomination Committee, Chair of the Compensation Committee, Member of the hhc Governance Committee and Member of the Independent Committee of Outside Directors

        Operating MetricsView all

        Products in Pipeline (Neurology)

        9
        30.8%

        Jul, 2020

        Filed Trials Products (Gastrointestinal)

        1

        Jul, 2018

        Trials Products Approved (Gastrointestinal)

        1
        66.7%

        Jul, 2019

        LocationsView all

        37 locations detected

        • Bunkyo City, Tokyo HQ

          Japan

          4 Chome-6-10 Koishikawa

        • Baltimore, MD

          United States

          6611 Tributary St #1

        • Cambridge, MA

          United States

          35 Cambridgepark Dr

        • Exton, PA

          United States

          210 Welsh Pool Rd

        • Raleigh, NC

          United States

          4130 Parklake Ave STE 500

        • Woodcliff Lake, NJ

          United States

          100 Tice Blvd

        and 31 others

        Eisai Financials

        Summary Financials

        Revenue (Q3, 2024)
        ¥177.7B
        Gross profit (Q3, 2024)
        ¥149.3B
        Net income (Q3, 2024)
        ¥6.6B
        Cash (Q3, 2023)
        ¥268.0B
        EBIT (Q3, 2024)
        ¥6.1B
        Enterprise value
        ($106.7B)

        Footer menu